Prospective, Observational, Multicenter Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation (ANIMA-R)
Latest Information Update: 21 Apr 2026
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms ANIMA-R
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 16 Apr 2026 Planned End Date changed from 31 Aug 2026 to 31 Dec 2026.
- 16 Apr 2026 Planned primary completion date changed from 31 Aug 2026 to 31 Dec 2026.
- 16 Apr 2026 Status changed from recruiting to active, no longer recruiting.